Can reactogenicity predict immunogenicity after COVID-19 vaccination?
Background/Aims This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Methods Adverse events were prospectively evaluated using an electronic diary in 135 healthy...
Guardado en:
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
The Korean Association of Internal Medicine
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a2c025690e8c4d0091640442ad05d2e9 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
id |
oai:doaj.org-article:a2c025690e8c4d0091640442ad05d2e9 |
---|---|
record_format |
dspace |
spelling |
oai:doaj.org-article:a2c025690e8c4d0091640442ad05d2e92021-11-08T00:59:06ZCan reactogenicity predict immunogenicity after COVID-19 vaccination?1226-33032005-664810.3904/kjim.2021.210https://doaj.org/article/a2c025690e8c4d0091640442ad05d2e92021-11-01T00:00:00Zhttp://www.kjim.org/upload/pdf/kjim-2021-210.pdfhttps://doaj.org/toc/1226-3303https://doaj.org/toc/2005-6648Background/Aims This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Methods Adverse events were prospectively evaluated using an electronic diary in 135 healthy adults who received a SARS-CoV-2 vaccine (AZD1222, AstraZeneca/Oxford, n = 42; or BNT162b2, Pfizer/BioNTech, n = 93). We semi-quantitatively measured anti-S1 immunoglobulin G (IgG) using an enzyme-linked immunosorbent assay at baseline, 3 weeks after the first dose of AZD1222 or BNT162b2, and 2 weeks after the second dose of BNT162b2. We evaluated the association between the maximum grade of local or systemic adverse events and the anti-S1 IgG optical density using multivariate linear regression with adjustment for age, sex, and use of antipyretics. Results The median age of the 135 vaccinees was 30 years (36 years in the AZD1222 group and 29 years in the BNT162b2 group) and 25.9% were male (9.5% in the AZD1222 group and 33.3% in the BNT162b2 group). Local and systemic adverse events were generally comparable after the first dose of AZD1222 and the second dose of BNT162b2. The grades of local and systemic adverse events were not significantly associated with anti-S1 IgG levels in the AZD1222 or BNT162b2 group. Conclusions Local and systemic reactogenicity may not be associated with humoral immunogenicity after SARS-CoV-2 vaccination.Young Hoon HwangKyoung-Ho SongYunsang ChoiSuryeong GoSu-Jin ChoiJongtak JungChang Kyung KangPyoeng Gyun ChoeNam-Joong KimWan Beom ParkMyoung-don OhThe Korean Association of Internal Medicinearticlecovid-19sars-cov-2immunogenicityvaccinedrug-related side effects and adverse reactionsenzyme-linked immunosorbent assayMedicineRENThe Korean Journal of Internal Medicine, Vol 36, Iss 6, Pp 1486-1491 (2021) |
institution |
DOAJ |
collection |
DOAJ |
language |
EN |
topic |
covid-19 sars-cov-2 immunogenicity vaccine drug-related side effects and adverse reactions enzyme-linked immunosorbent assay Medicine R |
spellingShingle |
covid-19 sars-cov-2 immunogenicity vaccine drug-related side effects and adverse reactions enzyme-linked immunosorbent assay Medicine R Young Hoon Hwang Kyoung-Ho Song Yunsang Choi Suryeong Go Su-Jin Choi Jongtak Jung Chang Kyung Kang Pyoeng Gyun Choe Nam-Joong Kim Wan Beom Park Myoung-don Oh Can reactogenicity predict immunogenicity after COVID-19 vaccination? |
description |
Background/Aims This study aimed to assess the association between local and systemic reactogenicity and humoral immunogenicity after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. Methods Adverse events were prospectively evaluated using an electronic diary in 135 healthy adults who received a SARS-CoV-2 vaccine (AZD1222, AstraZeneca/Oxford, n = 42; or BNT162b2, Pfizer/BioNTech, n = 93). We semi-quantitatively measured anti-S1 immunoglobulin G (IgG) using an enzyme-linked immunosorbent assay at baseline, 3 weeks after the first dose of AZD1222 or BNT162b2, and 2 weeks after the second dose of BNT162b2. We evaluated the association between the maximum grade of local or systemic adverse events and the anti-S1 IgG optical density using multivariate linear regression with adjustment for age, sex, and use of antipyretics. Results The median age of the 135 vaccinees was 30 years (36 years in the AZD1222 group and 29 years in the BNT162b2 group) and 25.9% were male (9.5% in the AZD1222 group and 33.3% in the BNT162b2 group). Local and systemic adverse events were generally comparable after the first dose of AZD1222 and the second dose of BNT162b2. The grades of local and systemic adverse events were not significantly associated with anti-S1 IgG levels in the AZD1222 or BNT162b2 group. Conclusions Local and systemic reactogenicity may not be associated with humoral immunogenicity after SARS-CoV-2 vaccination. |
format |
article |
author |
Young Hoon Hwang Kyoung-Ho Song Yunsang Choi Suryeong Go Su-Jin Choi Jongtak Jung Chang Kyung Kang Pyoeng Gyun Choe Nam-Joong Kim Wan Beom Park Myoung-don Oh |
author_facet |
Young Hoon Hwang Kyoung-Ho Song Yunsang Choi Suryeong Go Su-Jin Choi Jongtak Jung Chang Kyung Kang Pyoeng Gyun Choe Nam-Joong Kim Wan Beom Park Myoung-don Oh |
author_sort |
Young Hoon Hwang |
title |
Can reactogenicity predict immunogenicity after COVID-19 vaccination? |
title_short |
Can reactogenicity predict immunogenicity after COVID-19 vaccination? |
title_full |
Can reactogenicity predict immunogenicity after COVID-19 vaccination? |
title_fullStr |
Can reactogenicity predict immunogenicity after COVID-19 vaccination? |
title_full_unstemmed |
Can reactogenicity predict immunogenicity after COVID-19 vaccination? |
title_sort |
can reactogenicity predict immunogenicity after covid-19 vaccination? |
publisher |
The Korean Association of Internal Medicine |
publishDate |
2021 |
url |
https://doaj.org/article/a2c025690e8c4d0091640442ad05d2e9 |
work_keys_str_mv |
AT younghoonhwang canreactogenicitypredictimmunogenicityaftercovid19vaccination AT kyounghosong canreactogenicitypredictimmunogenicityaftercovid19vaccination AT yunsangchoi canreactogenicitypredictimmunogenicityaftercovid19vaccination AT suryeonggo canreactogenicitypredictimmunogenicityaftercovid19vaccination AT sujinchoi canreactogenicitypredictimmunogenicityaftercovid19vaccination AT jongtakjung canreactogenicitypredictimmunogenicityaftercovid19vaccination AT changkyungkang canreactogenicitypredictimmunogenicityaftercovid19vaccination AT pyoenggyunchoe canreactogenicitypredictimmunogenicityaftercovid19vaccination AT namjoongkim canreactogenicitypredictimmunogenicityaftercovid19vaccination AT wanbeompark canreactogenicitypredictimmunogenicityaftercovid19vaccination AT myoungdonoh canreactogenicitypredictimmunogenicityaftercovid19vaccination |
_version_ |
1718443302730072064 |